Hereditary hemochromatosis and β-thalassemia can both result in the inappropriately low production of the hormone hepcidin, which leads to an increase in intestinal absorption and excessive iron deposition in the parenchymal cells. To the best of our knowledge, there have been no reports on the coexistence of the two disorders in China. We herein report a case in a Chinese who presented with late-onset hepatic cirrhosis with hereditary hemochromatosis and β-thalassemia. We analyzed the pedigree of the two disorders and the iron status in his family members. Our case supports that a heterozygous H63D mutation can interact with β-thalassemia, leading to late-onset hemochromatosis.
Introduction
Hereditary hemochromatosis (HH) is the most common autosomal recessive disorder in Caucasians, affecting 1 in every 200-400 individuals (1) . In contrast, it is relatively rare in Asians (2) . HH is an inborn error of iron metabolism that is characterized by increased intestinal iron absorption, which leads to the progressive accumulation of iron in the body. Excess iron causes irreversible damage to various organs (3) . The hemochromatosis (HFE) gene has been identified to be mainly responsible for HH. Thus far, there have been no precise epidemiological data on the incidence of HH-related genotypes, and symptomatic HH is very rare in China. In a retrospective analysis of the Peking Study, which was conducted from 2002 to 2012, there were only 39 confirmed cases of clinical HH (4) . The β-thalassemias (β-thal) are a diverse group of disorders of hemoglobin synthesis, all of which result from the reduced output of the β chains of adult hemoglobin (5) . It is prevalent in Mediterranean countries, the Middle East, Central Asia, India, Southern China, and the Far East, as well as in countries along the north coast of Africa and South America (6) . The reported prevalence of β-thal in the Sichuan district of China is 3.2% (7) . The coexistence of the two disorders is very rare in China. In this report, we describe the case of a Chinese patient who presented with late-onset hepatic cirrhosis with HH and β-thal. We analyzed the mutations associated with these two disorders and the iron status of the patient's family members. Six members of 3 generations of the family underwent hemoglobin electrophoresis, the evaluation of their iron metabolism parameters, HFE gene exon sequencing and β-thal genetic testing. He also denied a dietary basis for his symptoms and hemorrhoid hemorrhage. Ultrasonography, which was performed in a local hospital, showed an irregular hepatic surface, hepatomegaly and ascites. A physical examination revealed an anemic appearance, but no signs of hemolysis or hemorrhage, such as fever, jaundice or purpura. Mild hepatosplenomegaly and pigmentation of the skin were observed. Laboratory studies revealed the following findings: hemoglobin (Hb), 6.1 g/dL; mean corpuscular volume (MCV), 77. Computed tomography (CT) revealed an uneven density of the liver parenchyma, a widened hepatic fissure, and a dilated portal vein (diameter: 1.4 cm). Nuclear magnetic resonance imaging (MRI) of the abdomen showed hepatic hemosiderosis complicated by cirrhosis (dark liver sign) and mild enlargement of the liver and spleen, ascites ( Figure A) . His iron overload was not solely explained by thalassemia, as he had been healthy during the prior 6 decades without transfusion or obvious hepatosplenomegaly. We therefore performed genetic testing for both HH and thalassemia. β-thal genetic testing using a polymerase chain reaction (PCR)-Reverse dot-blot assay showed a heterozygous 654 mutation. HFE genetic testing revealed a c.187C>G (p. H63D) missense heterozygous mutation by direct nucleotide sequencing ( Figure B) . Thus, the patient was diagnosed with β-thal minor and clinical HH, complicating decompensated cirrhosis. His symptoms were gradually relieved by iron chelation with deferoxamine mesylate (2,000 mg, daily) for three months, and his serum ferritin level decreased to 317 ng/mL. An additional five family members were studied after obtaining their written informed consent. The pattern of inheritance is shown in Figure C . The proband's son and younger daughter were both β-thal carriers with a heterozygous 654 mutation and a heterozygous H63D mutation, whereas the older daughter remained unaffected. We also checked the family for another 700 genes associated with hereditary hematological and immune deficiency disorders (including hepcidin (HAMP), transferrin receptor 2, and ferroportin) using next generation sequencing. We did not find any other known pathogenic abnormalities. Furthermore, the son had already developed a high ferritin level (551 ng/mL) but no manifestation of HH. None of his grandsons or granddaughters carried both mutations; moreover, they did not have symptoms or indices of an iron metabolism abnormality.
Discussion
HFE-hemochromatosis results from the mutations of 2 genes, C282Y and H63D (8) . Homozygous C282Y mutations are mainly responsible for clinical HH in Caucasians. However, this alone cannot account for iron overload in non-Caucasians because of the low prevalence (9) . Similarly to reports from Korea (10), Japan (11) and India (12, 13), a study of 1,615 healthy volunteers in the Chinese population (4) . According to the largest epidemiological dataset, the incidence of H63D heterozygotes and homozygotes in 1,615 Chinese individuals was 10.2% and 0.24%, respectively; which is much lower in comparison to Caucasians (24%), Native Americans (20%), and Hispanics (18%) (9, 14) . Thus, the effect of the H63D mutation on iron overload in Chinese individuals remains controversial. However, the coexistence of a H63D mutation with other disorders that predispose a person to iron absorption may have an interacting effect. The ferritin levels of patients with myelodysplastic syndrome (MDS) and aplastic anemia (AA), were higher among patients with H63D mutations (14, 17) . Similarly to MDS and AA, β-thal can also cause acquired iron overload through repeated transfusion and increased intestinal iron absorption. β-thal can be classified as thalassemia major, thalassemia intermedia, or thalassemia minor. Transfusion is usually unnecessary for thalassemia intermedia and thalassemia minor. Although these patients are at risk of iron overload secondary to increased intestinal iron absorption, severe iron overload and target organ damage are not common (18) . The role of H63D mutation polymorphism in β-thal major or carrier conditions has been studied in regions with a high incidence of H63D, such as in Southern Europe and Asia. Various studies have yielded conflicting conclusions (shown in Table 1 ): some studies from Italy, Portugal, India and Egypt suggested that iron overload might arise from the interacting effect of β-thal with homozygous or even heterozygous H 63 D mutations (13, (19) (20) (21) (22) (23) ; other reports from Italy, India, Thailand, Brazil and Spain indicated that the iron status was not related to the H63D mutation status (24) (25) (26) (27) (28) (29) . The discrepancy may be due to the sample size, hereditary background variations in different racial populations, the sex ratio and the severity of thalassemia. In these studies, patients with β-thal major seemed to have elevated ferritin levels if a H63D mutation was present.
Interestingly, Rees et al. published a study on a prototype family in which mutations associated with HFE and thalassemia had a co-effect on iron overload. The proband and his daughter had heterozygous C282Y mutations, and his mother had a homozygous C282Y mutation. Only the proband had β-thal and developed clinical hemochromatosis. His mother carried a homozygous C282Y mutation, without a β-thal mutation, and did not develop iron overload (30) . This finding strongly demonstrated the effect of the coexistence of HFE mutations and other diseases on the iron status. The coexistence of β-thal and clinical HH is very rare. There are only twenty-one reported cases involving the coexistence of β-thal and clinical HH, including eight C282 Y homozygotes, three C282Y heterozygotes, three compound heterozygotes, four H63D heterozygotes and three H63D homozygotes (25, (30) (31) (32) (33) (34) . Their clinical and laboratory data are shown in Table 2 . All of the patients developed severe iron overload or target organ damage. None of these individuals were from Chinese families.
In our report, the proband was diagnosed with β-thal minor. During the previous 60 years, he had only been a carrier of the β-thal mutation and had no symptoms of anemia or history of repeated blood transfusions. However, when he presented to our department with symptoms of anemia, hemochromatosis was confirmed based on an increased fer-ritin level (>2,000 ng/mL) and severe target organ damage (dark liver sign). This hemochromatosis might not have been completely secondary to β-thal. It is suggested that the coexistence of HFE mutations may be the genetic basis for severe iron overload and cirrhosis. "Compound" heterozygous involving different genes might have an interacting effect on iron overload and ultimately lead to a phenotypic abnormality. The patient's 44-year-old son and younger daughter presented with a similar mutation pattern, and his son had an elevated ferritin (551 ng/mL) level but no manifestations of HH. His daughter had no symptoms or indices of iron metabolism abnormality, possibly due to menometrorrhagia. The follow-up of the patient's children will be very important.
Thus, if a patient with thalassemia presents with iron overload that is inconsistent with their transfusion history, genetic screening should be performed to detect thalassemiarelated genes and a concomitant mutation in a second gene, either within the HFE gene or elsewhere, such as the genes encoding hepcidin, transferrin receptor 2, and ferroportin. Further epidemiological studies would help to differentiate the power of the interaction between HFE gene mutations and β-thal in Chinese populations and to establish preventive and therapeutic strategies for iron overload.
